Zimbabwe has turned down a substantial US health deal worth $367m (272 million pounds) spanning five years because of the United States' request for confidential biological samples.
This move was revealed after a internal memorandum from December was leaked, which showed President Emmerson Mnangagwa felt the agreement was "skewed".
A government spokesman later clarified that the United States was requesting health data for scientific study and commercial gain while was unwilling to share the benefits from any future treatments.
"We must now begin the challenging and unfortunate process of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for more talks to find a agreement suitable to all parties so the country's vital HIV treatment initiative can proceed.
Wider Background
This development follows a comparable situation in Kenya, where a court halted a related health funding agreement after legal challenges were raised about the security of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
The agency had managed aid for the US government, but Trump claimed its spending was "inefficient" and his government was pursuing direct bilateral deals to boost transparency and accountability.
Based on reports, 16 African countries have to date signed similar agreements, representing over $18.3bn in committed funds.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration would have delivered significant benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on antiretroviral therapy via American-funded initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to provide its biological resources and data over an extended period, without any equivalent promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"Put simply, our country would provide the basic resources for medical research with no assurance that the end products would be available to our people should a new disease outbreak arise."
Sovereignty and International Frameworks
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral deals were undermining structures already established via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system created to deal with future pandemics.
"This framework is designed to guarantee that when a country provides its data, the benefits – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome further discussions with our US partners on how future collaboration could be designed in a way that honours the sovereignty and dignity of each country."
Health Experts Response
Medical experts stated it acknowledged the government's concerns, but urged that negotiations need to persist considering a large portion of the nation's HIV programmes relied on foreign aid.
"If specific concerns exist, including those relating to information security or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," it added.
This impasse underscores the ongoing challenges between receiving crucial foreign assistance and protecting a country's data in an increasingly interconnected world.